Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 fat emulsion in post-operative cancer patients
NCT00292279Phase 3Completed
- Sponsor
- Sino-Swed Pharmaceutical Co., Ltd.
- Start
- Jun 2002
- Primary completion
- Nov 2003
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eicosapentaenoic acid + docosahexaenoic acid (2 arms), sponsored by Sino-Swed Pharmaceutical Co., Ltd. Primary endpoints: Infectious complication at 14 days and Systemic inflammatory response syndrome at 8 days. Started Jun 2002; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
Beyond the preview
Go deeper on NCT00292279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00292279.